Geron Corporation Announces Pricing of $150 Million Underwritten Offering of Common Stock and Pre-Funded WarrantsBusiness Wire • 03/19/24
Geron's stock soars 95% after FDA advisory panel votes in favor of blood-disorder drugMarket Watch • 03/15/24
Geron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDSBusiness Wire • 03/14/24
Geron Corporation Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial ResultsBusiness Wire • 02/28/24
Geron to Announce Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024Business Wire • 02/14/24
Geron Announces IMerge Phase 3 Presentations at ASH Highlighting Significant Durability of Transfusion Independence and Breadth of Effect Across MDS Subgroups with Imetelstat in Lower Risk MDSBusiness Wire • 12/11/23
Geron Announces Fifty Percent Enrollment in the Phase 3 IMpactMF Clinical Trial Evaluating Imetelstat in Patients with Relapsed/Refractory MyelofibrosisBusiness Wire • 12/06/23
Geron: Lancet Publication Derisks Imetelstat Opportunity Narrowly Makes Bull CaseSeeking Alpha • 12/04/23
Geron Announces Publication in The Lancet of Results from the IMerge Phase 3 Clinical Trial Evaluating Imetelstat in Lower Risk MDSBusiness Wire • 12/04/23